Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sniffing out a new COVID defense: early nasal vaccine trial begins

NCT ID NCT07416539

Summary

This is an early-stage study testing a new COVID-19 vaccine given as a nasal spray. Researchers want to see if two slightly different formulas are safe and can trigger a good immune response in healthy adults. The study will give participants two doses and track them for side effects and how well their bodies fight the virus.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kuopio University Hospital, ENT policlinic

    RECRUITING

    Kuopio, Northern Savonia, 70210, Finland

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.